Patent · US Active

PDE10 inhibitors and related compositions and methods

US8685975B2 · kind B2 · utility

6Cited by
10References
40Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 16, 2012
Grant dateApr 1, 2014
Priority date
Expiry dateNov 16, 2032

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.